Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 21 versus JENCYCLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 21 versus JENCYCLA.
DEMULEN 1/35-21 vs JENCYCLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
None Documented
None Documented
Ethinyl estradiol: 13±3 hours (terminal); norethindrone: 8±3 hours. Steady-state achieved after ~5 days.
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Renal (primarily as glucuronide and sulfate conjugates): ~60%; fecal: ~40%
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive